SEND AN EMAIL
Use the button below to send an email to your colleagues about the trial. This email template is prepopulated with basic information about the trial and a link to the website where your colleagues can learn more.
SHARE THE STUDY
The Intrepid transcatheter mitral valve replacement (TMVR) system integrates self-expanding stent technology with a tissue heart valve to facilitate minimally invasive, catheter-based implantation.
The prosthesis is compressed inside a hollow delivery catheter and implantation is completed through trans-apical access. It is designed to engage and conform to the native annulus without need for additional sutures, tethers, or anchors.
The device design features:
Read through the inclusion/exclusion criteria and view more resources to help you determine if you have patients who are eligible to participate in the trial.
U.S. Census Bureau. Statistical Abstract of the U.S.: 2006, Table 12.
Nkomo VT, et al. Lancet. 2006;368:1005-1011.